Please wait a minute...
浙江大学学报(医学版)  2022, Vol. 51 Issue (4): 515-520    DOI: 10.3724/zdxbyxb-2022-0099
综述     
生长激素以外的促生长疗法研究进展
薛初晴,傅君芬()
浙江大学医学院附属儿童医院内分泌科 国家儿童健康与疾病临床医学研究中心 国家儿童区域医疗中心,浙江 杭州 310052
Progress on growth promoting therapies other than growth hormone
XUE Chuqing,FU Junfen()
Department of Endocrinology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Regional Medical Center for Children, Hangzhou 310052, China
 全文: PDF(503 KB)   HTML( 189 )
摘要:

重组人生长激素是身材矮小症儿童的经典治疗药物。近年来随着儿童生长机制的进一步探明,生长激素以外的促生长疗法的研究取得较大进展。重组人胰岛素样生长因子1是治疗原发性胰岛素样生长因子1缺乏的主要药物。C型钠尿肽为因软骨发育不全导致身材矮小症儿童提供了治疗选择。生长激素释放肽类似物能刺激生长激素释放,用于促生长治疗。此外,促性腺激素释放激素激动剂、芳香化酶抑制剂等可延缓患儿骨龄进展,对改善终身高有一定益处。现就这些除生长激素以外的促生长疗法研究进展进行综述,以期为临床身材矮小症患儿的治疗提供更多选择。

关键词: 身材矮小症重组人胰岛素样生长因子-1C型钠尿肽生长激素释放肽类似物促性腺激素释放激素激动剂芳香化酶抑制剂综述    
Abstract:

Recombinant human growth hormone is a classical therapeutic drug for children with short stature. In recent years, as the mechanism of growth in children has been further explored, growth-promoting therapies other than growth hormone have made great progress. Recombinant human insulin-like growth factor (IGF)-1 is the main treatment for primary IGF-1 deficiency, and C-type natriuretic peptide (CNP) offers a therapeutic option for children with short stature due to chondrodysplasia. Growth hormone-releasing peptide analogues stimulate growth hormone release and may be used for growth-promoting therapy. In addition, gonadotropin-releasing hormone analogue (GnRHa) and aromatase inhibitors may delay the bone age in children and may be beneficial in improving final height. In this article, the research progress of growth-promoting therapies other than growth hormones is reviewed to provide more options for the clinical treatment of children with short stature.

Key words: Short stature    Recombinant human insulin-like growth factor-1    C-type natriuretic peptide    Growth hormone-releasing peptide analogue    Gonadotropin releasing hormone agonist    Aromatase inhibitor    Review
收稿日期: 2022-03-11 出版日期: 2022-11-16
CLC:  R588  
基金资助: “十三五”国家科技支撑计划(2016YFC1305301)
通讯作者: 傅君芬     E-mail: fjf68@zju.edu.cn
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  
薛初晴
傅君芬

引用本文:

薛初晴,傅君芬. 生长激素以外的促生长疗法研究进展[J]. 浙江大学学报(医学版), 2022, 51(4): 515-520.

XUE Chuqing,FU Junfen. Progress on growth promoting therapies other than growth hormone. J Zhejiang Univ (Med Sci), 2022, 51(4): 515-520.

链接本文:

https://www.zjujournals.com/med/CN/10.3724/zdxbyxb-2022-0099        https://www.zjujournals.com/med/CN/Y2022/V51/I4/515

1 AĞıRDIL Y . The growth plate: a physiologic overview[J]EFORT Open Rev, 2020, 5( 8): 498-507.
doi: 10.1302/2058-5241.5.190088
2 PETRICZKO E , JACKOWSKI T , HORODNICKA-JÓZWA A , et al.Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation——first three years of Polish experience[J]Endokrynologia Polska, 2019, 70( 1): 20-27.
doi: 10.5603/EP.a2018.0074
3 PFÄFFLE R, KIESS W. GH and IGF-1 replacement in children[J]. Handb Exp Pharmacol, 2020, 261: 67-86
4 BANG P , POLAK M , WOELFLE J , et al.Effectiveness and safety of rhIGF-1 therapy in children: the european increlex® growth forum database experience[J]Horm Res Paediatr, 2015, 83( 5): 345-357.
doi: 10.1159/000371798
5 BACKELJAUW P F , KUNTZE J , FRANE J , et al.Adult and near-adult height in patients with severe insulin-like growth factor-Ⅰ deficiency after long-term therapy with recombinant human insulin-like growth factor- Ⅰ[J]Horm Res Paediatr, 2013, 80( 1): 47-56.
doi: 10.1159/000351958
6 BRAHMKHATRI V P , PRASANNA C , ATREYA H S . Insulin-like growth factor system in cancer: novel targeted therapies[J]Biomed Res Int, 2015, 538019.
doi: 10.1155/2015/538019
7 BANG P , WOELFLE J , PERROT V , et al.Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome[J]Eur J Endocrinol, 2021, 184( 2): 267-276.
doi: 10.1530/EJE-20-0325
8 LUI J C , COLBERT M , CHEUNG C S F , et al.Cartilage-targeted IGF-1 treatment to promote longitudinal bone growth[J]Mol Ther, 2019, 27( 3): 673-680.
doi: 10.1016/j.ymthe.2019.01.017
9 SAVARIRAYAN R , IRVING M , BACINO C A , et al.C-type natriuretic peptide analogue therapy in children with achondroplasia[J]N Engl J Med, 2019, 381( 1): 25-35.
doi: 10.1056/NEJMoa1813446
10 WENDT D J , DVORAK-EWELL M , BULLENS S , et al.Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism[J]J Pharmacol Exp Ther, 2015, 353( 1): 132-149.
doi: 10.1124/jpet.114.218560
11 SAVARIRAYAN R , TOFTS L , IRVING M , et al.Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial[J]Lancet, 2020, 396( 10252): 684-692.
doi: 10.1016/S0140-6736(20)31541-5
12 DUGGAN S . Vosoritide: first approval[J]Drugs, 2021, 81( 17): 2057-2062.
doi: 10.1007/s40265-021-01623-w
13 The U.S. Food and Drug Administration. FDA approves first drug to improve growth in children with most common form of dwarfism[EB/OL]. (2021-11-19)[2022-08-31]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism
14 PERCHARD R, CLAYTON PE. Ghrelin and growth[J]. Endocr Dev, 2017, 32: 74-86
15 PRADHAN G , SAMSON S L , SUN Y . Ghrelin: much more than a hunger hormone[J]Curr Opin Clin Nutr Metab Care, 2013, 16( 6): 619-624.
doi: 10.1097/MCO.0b013e328365b9be
16 GARIN M C , BURNS C M , KAUL S , et al.The human experience with ghrelin administration[J]J Clin Endocrinol Metab, 2013, 98( 5): 1826-1837.
doi: 10.1210/jc.2012-4247
17 LARON Z , FRENKEL J , DEGHENGHI R , et al.Intranasal administration of the GHRP hexarelin accelerates growth in short children[J]Clin Endocrinol, 1995, 43( 5): 631-635.
doi: 10.1111/j.1365-2265.1995.tb02929.x
18 MERICQ V ́ , CASSORLA F , SALAZAR T , et al.Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children[J]J Clin Endocrinol Metab, 1998, 83( 7): 2355-2360.
doi: 10.1210/jcem.83.7.4969
19 CODNER E , CASSORLA F , TIULPAKOV A N , et al.Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor Ⅰ axis in growth hormone-deficient children[J]Clin Pharmacol Ther, 2001, 70( 1): 91-98.
doi: 10.1067/mcp.2001.116514
20 FU J , ZHANG J , CHEN R , et al.Long-term outcomes of treatments for central precocious puberty or early and fast puberty in Chinese girls[J]J Clin Endocrinol Metab, 2020, 105( 3): 705-715.
doi: 10.1210/clinem/dgz027
21 VURALLI D , GONC N E , OZON Z A , et al.Which parameters predict the beneficial effect of GnRHa treatment on height in girls with central precocious puberty?[J]Clin Endocrinol, 2021, 94( 5): 804-810.
doi: 10.1111/cen.14420
22 WIT J M , OOSTDIJK W . Novel approaches to short stature therapy[J]Best Pract Res Clin Endocrinol Metab, 2015, 29( 3): 353-366.
doi: 10.1016/j.beem.2015.01.003
23 KHAWAJA N , OWAINEH H , BATIEHA A , et al.The effect of gonadotropin-releasing hormone analogue on final adult height in children with idiopathic short stature[J]Med Princ Pract, 2019, 28( 6): 509-516.
doi: 10.1159/000499929
24 LI S , WANG X , ZHAO Y , et al.Combined therapy with GnRH analogue and growth hormone increases adult height in children with short stature and normal pubertal onset[J]Endocrine, 2020, 69( 3): 615-624.
doi: 10.1007/s12020-020-02375-5
25 DE SANCTIS V, SOLIMAN AT, DI MAIO S, et al. Long-term effects and significant adverse drug reactions (ADRs) associated with the use of gonadotropin-releasing hormone analogs (GnRHa) for central precocious puberty: a brief review of literature[J]. Acta Biomed, 2019, 90(3): 345-359
26 WIT J M , HERO M , NUNEZ S B . Aromatase inhibitors in pediatrics[J]Nat Rev Endocrinol, 2012, 8( 3): 135-147.
doi: 10.1038/nrendo.2011.161
27 MCGRATH N , O’GRADY M J . Aromatase inhibitors for short stature in male children and adolescents[J]Cochrane Database Systatic Rev, 2015, 2015( 10): CD010888.
doi: 10.1002/14651858.CD010888.pub2
28 WICKMAN S , SIPILÄ I , ANKARBERG-LINDGREN C , et al.A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial[J]Lancet, 2001, 357( 9270): 1743-1748.
doi: 10.1016/S0140-6736(00)04895-9
29 HERO M , NORJAVAARA E , DUNKEL L . Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial[J]J Clin Endocrinol Metab, 2005, 90( 12): 6396-6402.
doi: 10.1210/jc.2005-1392
30 MAURAS N , ROSS J L , GAGLIARDI P , et al.Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature[J]J Clin Endocrinol Metab, 2016, 101( 12): 4984-4993.
doi: 10.1210/jc.2016-2891
31 王春林, 梁 黎. 第三代非甾体类芳香化酶抑制剂在儿科内分泌临床应用的再认识[J]. 浙江大学学报(医学版), 2020, 49(3): 75-282
WANG Chunlin, LIANG Li. Reconsideration of the third-generation non-steroidal aromatase inhibitors in pediatrics[J]. Journal of Zhejiang University (Medical Sciences), 2020, 49(3): 275-282. (in Chinese)
32 孔元梅, 陈 虹, 梁 黎, 等. 芳香化酶抑制剂联合生长激素治疗青春期身材矮小症男性患儿的临床研究[J]. 浙江大学学报(医学版), 2020, 49(3): 283-290
KONG Yuanmei, CHEN Hong, LIANG Li, et al. Aromatase inhibitors combined with growth hormone in treatment of adolescent boys with short stature[J]. Journal of Zhejiang University (Medical Sciences), 2020, 49(3): 283-290. (in Chinese)
[1] 李芸,陈新. T淋巴细胞体外发育方法的研究进展[J]. 浙江大学学报(医学版), 2022, 51(4): 491-499.
[2] 周璐佳,梁景岩,熊天庆. 间充质干细胞来源的外泌体调节缺血性脑卒中后炎症反应的研究进展[J]. 浙江大学学报(医学版), 2022, 51(4): 500-506.
[3] 袁伟,张世忠,主鸿鹄. FLT3抑制剂治疗急性髓系白血病患者研究进展[J]. 浙江大学学报(医学版), 2022, 51(4): 507-514.
[4] 邹杰林,毛靖,石鑫. 牙髓-牙本质复合体再生的影响因素及其生物学策略[J]. 浙江大学学报(医学版), 2022, 51(3): 350-361.
[5] 孙萍萍,邹炜. 活细胞RNA成像技术及其在生物医学中应用研究进展[J]. 浙江大学学报(医学版), 2022, 51(3): 362-372.
[6] 邵玥明,荀静娜,陈军,卢洪洲. 人类免疫缺陷病毒感染早期启动抗逆转录病毒治疗的意义[J]. 浙江大学学报(医学版), 2022, 51(3): 373-379.
[7] 杨朝森,张晓明. 囊泡转运在肌萎缩侧索硬化中的作用研究进展[J]. 浙江大学学报(医学版), 2022, 51(3): 380-387.
[8] 刘志超,钱周旸,王英男,王慧明. 程序性坏死在骨关节炎病理机制和治疗中的作用[J]. 浙江大学学报(医学版), 2022, 51(2): 261-265.
[9] 李健宜,佟丹丹,林俊生. 恶性肿瘤饥饿疗法研究现状[J]. 浙江大学学报(医学版), 2022, 51(2): 241-250.
[10] 叶柏新,胡永仙,张明明,黄河. 脂质纳米粒-mRNA递送系统及其在嵌合抗原受体T细胞治疗中的应用[J]. 浙江大学学报(医学版), 2022, 51(2): 185-191.
[11] 刘娇,涂晓璇,刘璐璐,方维佳. 嵌合抗原受体T细胞治疗恶性实体瘤新进展[J]. 浙江大学学报(医学版), 2022, 51(2): 175-184.
[12] 胡珂嘉,黄玥,胡永仙,黄河. 嵌合抗原受体T细胞治疗血液系统恶性肿瘤研究进展[J]. 浙江大学学报(医学版), 2022, 51(2): 192-203.
[13] 张少琪,孙洁. 纳米药物递送系统在急性髓细胞性白血病治疗中的应用[J]. 浙江大学学报(医学版), 2022, 51(2): 233-240.
[14] 邢敬慈,揭伟. 甲基转移酶SET结构域家族及其在心血管发育和疾病中的作用[J]. 浙江大学学报(医学版), 2022, 51(2): 251-260.
[15] 刘德坤,刘佳丽,张丹,杨雯晴. 细胞衰老与动脉粥样硬化的相关研究进展[J]. 浙江大学学报(医学版), 2022, 51(1): 95-101.